Ernest Borden, M.D.

• Cleveland Clinic Foundation, Director of the Center for Hematology and Oncology Molecular Therapeutics
• Practicing Oncologist with >20 years research and clinical trials experience with immunomodulatory therapy in cancer

Eleanor Fish, Ph.D.

• University of Toronto, Head, Division of Cellular & Molecular Biology
• Immunologist, infectious diseases specialist and expert in activation of immune effector cells such as NK cells

Heinz Gschwend, Ph.D.

• Independent consultant
• Dr. Gschwend has extensive experience with early stage biopharmaceutical and biotechnology companies including his time as Head of Chemistry and Head of Central Research at Ciba Pharma and Head of Research at Arris Pharma (now AxYs). During his career, he was responsible for the development of over eighty clinical candidates, resulting in two drugs currently on the market (Benazepril and Letrozole).

Daniel Herschlag, Ph.D.

• Stanford University, Professor of Biochemistry
• Dr. Herschlag’s Lab is dedicated to understanding the fundamental behavior of RNA and proteins and, in turn, how these behaviors determine and impact biological catalysis and biology. The lab takes an interdisciplinary approach; spanning and integrating physics, chemistry and biology.

Cheng Kao, Ph.D.

• Indiana University, Professor, Molecular and Cellular Biochemistry
• Dr. Kao’s team has elucidated how the HCV polymerase recognizes HCV RNAs and initiates RNA synthesis, and his work has direct relevance to anti-HCV drug design.

Hans Maag, Ph.D.

• Independent consultant
• Dr. Maag has specializes in medicinal chemistry, drug discovery and early clinical development of medicines. He has 35 years of experience in anti-viral drug discovery at Syntex and Roche and has participated and led many project teams, from early drug discovery through preclinical and clinical development, notably resulting in the development and commercialization of Valcyte®.

Milton Taylor

• Indiana University, Professor emeritus
• Milton Taylor has researched and taught molecular biology at IU since 1967. During this time, he has worked in the areas of somatic cell genetics, viral replication, and the effects of interferon on viral replication and the immune system.

Myron Tong, M.D., Ph.D.

• University of California Los Angeles, Director, Asian Liver Program
• A world-leading hepatologist, Dr. Tong has specialized in liver-disease research and treatment for more than 25 years. His research efforts include anti-viral treatment of patients with hepatitis B and hepatitis C, and he is heavily involved in the treatment of patients with hepatocellular carcinoma at UCLA.